FANCB and neoplasm: When the PEG contents in the formulations were 5%, the structure was brush-like (Allen et al., 2002), which enabled the BsAbs to be non-covalently bound to methoxy terminus of the straight PEG chain via the anti-mPEG Fab fragments of BsAbs, to enhance active targeting of the mPEGylated NCs to the tumors via the anti-tumor scFv fragment of the BsAbs.